BC Week In Review | Mar 30, 2017
Company News

Emergent BioSolutions, HHS infectious news

Emergent signed a two-year contract with HHS’s Biomedical Advanced Research and Development Authority (BARDA) to deliver BioThrax to the U.S. Strategic National Stockpile (SNS). The contract is valued at $100 million. BioThrax is approved for...
BC Week In Review | Jan 6, 2017
Company News

Emergent BioSolutions infectious news

Emergent signed a follow-on contract with the CDC worth up to $911 million to supply 29.4 million doses of BioThrax to the U.S. Strategic National Stockpile through September 2021. BioThrax is approved for pre-or post-exposure...
BC Week In Review | Oct 10, 2016
Company News

Emergent BioSolutions, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) granted Emergent a contract worth up to $1.6 billion to develop NuThrax ( AV7909 ). Emergent said the contract includes about $200 million over five years to develop...
BC Extra | Sep 30, 2016
Financial News

Emergent lands BARDA contract for new anthrax vaccine

Emergent BioSolutions Inc. (NYSE:EBS) gained $3.77 (14%) to $31.53 on Friday after it said it signed a contract with HHS's Biomedical Advanced Research and Development Authority worth up to $1.6 billion to develop NuThrax ( AV7909...
BC Week In Review | Aug 22, 2016
Clinical News

Px563L: Phase Ia data

A double-blind, placebo-controlled, U.S. Phase Ia trial in about 54 healthy volunteers showed that 2 doses of 10 or 80 ug intramuscular Px563L given 28 days apart led to a TNA NF50 value of >=0.56...
BC Extra | Aug 8, 2016
Clinical News

Pfenex regains rights to Lucentis biosimilar, reports data

Pfenex Inc. (NYSE-M:PFNX) regained worldwide rights to PF582 and said the biosimilar of Lucentis ranibizumab met the primary endpoint of demonstrating similar safety and tolerability to its reference product in a Phase I/II study to...
BC Week In Review | Dec 7, 2015
Clinical News

BioThrax regulatory update

FDA approved an sBLA from Emergent for BioThrax to prevent disease following suspected or confirmed Bacillus anthracis exposure in patients ages 18-65. The vaccine is approved in the U.S. for pre-exposure prophylaxis of disease in...
BC Week In Review | Sep 14, 2015
Company News

Emergent BioSolutions cancer, hematology news

Emergent will spin out its biosciences business into a stand-alone, publicly traded company. The spinout will focus on oncology and hematology therapeutics and will receive $50-$70 million in cash from Emergent. The spinout will gain...
BC Week In Review | Mar 30, 2015
Company News

Emergent BioSolutions Inc, U.S. Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded Emergent a contract valued at $31 million to develop NuThrax ( AV7909 ) for post-exposure prophylaxis of anthrax disease. The contract will support process validation, consistency lot manufacture,...
BC Extra | Mar 26, 2015
Company News

Emergent's anthrax treatment gets FDA nod

FDA approved a BLA for Anthrasil anthrax immune globulin IV (AIGIV) from Emergent BioSolutions Inc. (NYSE:EBS) to treat inhaled anthrax. The drug, developed using plasma collected from healthy donors vaccinated with the company's BioThrax , has...
Items per page:
1 - 10 of 119